Evidence mapPaperPMID 35836845Full record

ReviewAmerican journal of translational research2022

Mechanistic insights into the role of FOXO in diabetic retinopathy.

Tapan Behl, Muskan Wadhwa, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Saurabh Bhatia, Ahmed Al-Harrasi, Lotfi Aleya, Simona Bungau

Open access · greenAbstract readReview
In one paragraph

Review in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Tapan BehlChitkara College of Pharmacy, Chitkara University Punjab 140401, India.
Muskan WadhwaChitkara College of Pharmacy, Chitkara University Punjab 140401, India.
Aayush SehgalChitkara College of Pharmacy, Chitkara University Punjab 140401, India.
Sukhbir SinghChitkara College of Pharmacy, Chitkara University Punjab 140401, India.
Neelam SharmaChitkara College of Pharmacy, Chitkara University Punjab 140401, India.
Saurabh BhatiaNatural & Medical Sciences Research Centre, University of Nizwa Nizwa 342001, Oman.
Ahmed Al-HarrasiNatural & Medical Sciences Research Centre, University of Nizwa Nizwa 342001, Oman.
Lotfi AleyaChrono-Environment Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University France.
Simona BungauDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea Oradea 410028, Romania.
Chitkara University · INUniversity of Nizwa · OMCentre National de la Recherche Scientifique · FRUniversity of Oradea · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM), a metabolic disorder characterized by insulin-deficiency or insulin-resistant conditions. The foremost microvascular complication of diabetes is diabetic retinopathy (DR). This is a multifaceted ailment mainly caused by the enduring adverse effects of hyperglycaemia. Inflammation, oxidative stress, and advanced glycation products (AGES) are part and parcel of DR pathogenesis. In regulating many cellular and biological processes, the family of fork-head transcription factors plays a key role. The current review highlights that FOXO is a requisite regulator of pathways intricate in diabetic retinopathy on account of its effect on microvascular cells inflammatory and apoptotic gene expression, and FOXO also has the foremost province in regulating cell cycle, proliferation, apoptosis, and metabolism. Blockage of insulin turns into an exaggerated level of glucose in the bloodstream and can upshot into the exaggerated triggering of FOXO1, which can ultimately uplift the production of several factors of apoptosis and inflammation, such as TNF-α, NF-kB, and various others, as well as reactive oxygen species, which can also come up with diabetic retinopathy. The current review also focuses on various therapies which can be used in the future, like SIRT1 signalling, resveratrol, retinal VEGF, etc., which can be used to suppress FOXO over activation and can prevent the progression of diabetic complications viz. diabetic retinopathy.

Indexed as

advanced glycation end-product (AGE)Diabetes mellitusdiabetic retinopathyFOXOtumor necrosis factor (TNF)-α

Identifiers

PMID35836845
PMCPMC9274583
OpenAlexW4285613256

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.